Dexcom raises revenue and margin targets and authorizes a $1 billion buyback
Dexcom ($DXCM) lifted its 2026 sales forecast to $5.20–$5.25 billion, raising the midpoint, and increased its adjusted operating-margin target to approximately 24%. Third-quarter 2026 revenue increased 11% to $1.34 billion, with US growth of 14% outpacing international growth of 5%. Reported operating income reached $327.2 million, equivalent to 24.3% of sales, an improvement of 4.2 percentage points from a year earlier. The glucose-monitoring company also authorized repurchases of up to $1 bill
0